Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice

被引:15
作者
McLarty, Kristin [1 ,2 ]
Moran, Matthew D. [1 ,2 ]
Scollard, Deborah A. [8 ]
Chan, Conrad [8 ]
Sabha, Nesrin [3 ]
Mukherjee, Joydeep [3 ]
Guha, Abhijit [3 ]
McLaurin, JoAnne [4 ]
Nitz, Mark [5 ]
Houle, Sylvain [1 ,2 ]
Wilson, Alan A. [1 ,2 ]
Reilly, Raymond M. [6 ,7 ,8 ]
Vasdev, Neil [1 ,2 ]
机构
[1] Ctr Addict & Mental Hlth, PET Ctr, Toronto, ON M5T 1R8, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON M5T 1R8, Canada
[3] Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada
[4] Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada
[5] Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada
[6] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON M5G 2M9, Canada
[7] Univ Toronto, Dept Med Imaging, Toronto, ON M5S 3M2, Canada
[8] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 3M2, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
F-18]-scyllo-inositol; F-18]-FDG; PET; Breast cancer; Glioma; Inflammation; SMALL ANIMAL PET; F-18-FDG PET; FDG-PET; TUMORS; ONCOLOGY; MODEL;
D O I
10.1016/j.nucmedbio.2011.02.017
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The aim of the study was to evaluate the uptake of [F-18]-1-deoxy-1-fluoro-scyllo-inositol ([F-18]-scyllo-inositol) in human breast cancer (BC) and glioma xenografts, as well as in inflammatory tissue, in immunocompromised mice. Studies of [F-18]-2-fluoro-2-deoxy-D-glucose ([F-18]-FDG) under the same conditions were also performed. Methods: Radiosynthesis of [F-18]-scyllo-inositol was automated using a commercial synthesis module. Tumour, inflammation and normal tissue uptakes were evaluated by biodistribution studies and positron emission tomography (PET) imaging using [F-18]-scyllo-inositol and [F-18]-FDG in mice bearing subcutaneous MDA-MB-231, MCF-7 and MDA-MB-361 human BC xenografts, intracranial U-87 MG glioma xenografts and turpentine-induced inflammation. Results: The radiosynthesis of [F-18]-scyllo-inositol was automated with good radiochemical yields (24.6%+/- 3.3%, uncorrected for decay, 65 +/- 2 min, n=5) and high specific activities (>= 195 GBq/mu mol at end of synthesis). Uptake of [F-18]-scyllo-inositol was greatest in MDA-MB-231 BC tumours and was comparable to that of [F-18]-FDG (4.6 +/- 0.5 vs. 5.5 +/- 2.1 %ID/g, respectively; P=.40), but was marginally lower in MDA-MB-361 and MCF-7 xenografts. Uptake of [F-18]-scyllo-inositol in inflammation was lower than [F-18]-FDG. While uptake of [F-18]-scyllo-inositol in intracranial U-87 MG xenografts was significantly lower than [F-18]-FDG, the tumour-to-brain ratio was significantly higher (10.6 +/- 2.5 vs. 2.1 +/- 0.6; P=.001). Conclusions: Consistent with biodistribution studies, uptake of [F-18]-scyllo-inositol was successfully visualized by PET imaging in human BC and glioma xenografts, with lower accumulation in inflammatory tissue than [F-18]-FDG. The tumour-to-brain ratio of [F-18]-scyllo-inositol was also significantly higher than that of [F-18]-FDG for visualizing intracranial glioma xenografts in NOD SCID mice, giving a better contrast. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:953 / 959
页数:7
相关论文
共 20 条
[1]   Clinical applications of PET in brain tumors [J].
Chen, Wei .
JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (09) :1468-1481
[2]   Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences [J].
Coenen, H. H. ;
Elsinga, P. H. ;
Iwata, R. ;
Kilbourn, M. R. ;
Pillai, M. R. A. ;
Rajan, M. G. R. ;
Wagner, H. N., Jr. ;
Zaknun, J. J. .
NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (07) :727-740
[3]  
Cook GJR, 2007, Q J NUCL MED MOL IM, V51, P235
[4]   Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance [J].
Fisher, SK ;
Novak, JE ;
Agranoff, BW .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (04) :736-754
[5]   Recommendations on the use of 18F-FDG PET in oncology [J].
Fletcher, James W. ;
Djulbegovic, Benjamin ;
Soares, Heloisa P. ;
Siegel, Barry A. ;
Lowe, Val J. ;
Lyman, Gary H. ;
Coleman, R. Edward ;
Wahl, Richard ;
Paschold, John Christopher ;
Avrill, Norbert ;
Einhorn, Lawrence H. ;
Suh, W. Warren ;
Samson'O, David ;
Delbekell, Dominique ;
Gorman, Mark ;
Shields, Anthony F. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (03) :480-508
[6]  
Fueger BJ, 2006, J NUCL MED, V47, P999
[7]  
Hawkes CA, 2011, CURR ALZHEI IN PRESS
[8]   Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F] FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse model [J].
Liu, Ren-Shyan ;
Chou, Ta-Kai ;
Chang, Chih-Hsien ;
Wu, Chun-Yi ;
Chang, Chi-Wei ;
Chang, Tsui-Jung ;
Wang, Shih-Jen ;
Lin, Wuu-Jyh ;
Wang, Hsin-Ell .
NUCLEAR MEDICINE AND BIOLOGY, 2009, 36 (03) :305-312
[9]   In vivo imaging in a murine model of glioblastoma [J].
Lost, Sarah C. ;
Wanebo, John E. ;
Song, Sheng-Kwei ;
Chicoine, Michael R. ;
Rich, Keith A. ;
Woolsey, Thomas A. ;
Lewis, Jason S. ;
Mach, Robert H. ;
Xu, Jinbin ;
Garbow, Joel R. .
NEUROSURGERY, 2007, 60 (02) :360-370
[10]   18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice [J].
McLarty, Kristin ;
Fasih, Aisha ;
Scollard, Deborah A. ;
Done, Susan J. ;
Vines, Douglass C. ;
Green, David E. ;
Costantini, Danny L. ;
Reilly, Raymond M. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (11) :1848-1856